Adc Therapeutics Sa logo

Adc Therapeutics Sa Share Price Today

(NASDAQ: ADCT)

Adc Therapeutics Sa share price is $1.69 & ₹146.98 as on 6 Mar 2025, 2.30 'hrs' IST

$1.69

-0.1

(-5.59%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Adc Therapeutics Sa share price in Dollar and Rupees. Guide to invest in Adc Therapeutics Sa stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Adc Therapeutics Sa, along with analyst recommendations, forecasts, and comprehensive financials.

Adc Therapeutics Sa share price movements

  • Today's Low: $1.67
    Today's High: $1.77

    Day's Volatility :5.93%

  • 52 Weeks Low: $1.39
    52 Weeks High: $5.38

    52 Weeks Volatility :74.16%

Adc Therapeutics Sa (ADCT) Returns

PeriodAdc Therapeutics SaSector (Health Care)Index (Russel 2000)
3 Months
-11.98%
3.7%
0.0%
6 Months
-40.28%
-2.8%
0.0%
1 Year
-66.2%
2.5%
0.0%
3 Years
-87.93%
12.9%
-11.6%

Adc Therapeutics Sa (ADCT) Key Statistics

in dollars & INR

Previous Close
$1.79
Open
$1.79
Today's High
$1.77
Today's Low
$1.665
Market Capitalization
$173.1M
Today's Volume
$304.2K
52 Week High
$5.38
52 Week Low
$1.39
Revenue TTM
$70.7M
EBITDA
$-136.9M
Earnings Per Share (EPS)
$-2.69
Profit Margin
-300.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-705.53%

How to invest in Adc Therapeutics Sa Stock (ADCT) from India?

It is very easy for Indian residents to invest directly in Adc Therapeutics Sa from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Adc Therapeutics Sa stock in both Indian Rupees (INR) and US Dollars (USD). Search for Adc Therapeutics Sa or ADCT on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Adc Therapeutics Sa or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Adc Therapeutics Sa shares which would translate to 0.515 fractional shares of Adc Therapeutics Sa as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Adc Therapeutics Sa, in just a few clicks!

Returns in Adc Therapeutics Sa (ADCT) for Indian investors in Rupees

The Adc Therapeutics Sa stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Adc Therapeutics Sa investment value today

Current value as on today

₹38,749

Returns

₹61,251

(-61.25%)

Returns from Adc Therapeutics Sa Stock

₹66,200 (-66.2%)

Dollar Returns

₹4,949 (+4.95%)

Indian investors sentiment towards Adc Therapeutics Sa (ADCT)

36%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Adc Therapeutics Sa Stock from India on INDmoney has increased by 36% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Adc Therapeutics Sa

  • Redmile Group, LLC

    16.20%

  • Prosight Management, LP

    9.84%

  • Orbimed Advisors, LLC

    6.17%

  • BlackRock Inc

    5.18%

  • Morgan Stanley - Brokerage Accounts

    4.09%

  • Woodline Partners LP

    2.00%

Analyst Recommendation on Adc Therapeutics Sa

Buy

    83%Buy

    16%Hold

    0%Sell

Based on 12 Wall street analysts offering stock ratings for Adc Therapeutics Sa(by analysts ranked 0 to 5 stars)

Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
8
Hold
2
2
2
Sell
0
0
0

Analyst Forecast on Adc Therapeutics Sa Stock (ADCT)

What analysts predicted

Upside of 420.71%

Target:

$8.80

Current:

$1.69

Insights on Adc Therapeutics Sa Stock (Ticker Symbol: ADCT)

  • Price Movement

    In the last 7 days, ADCT stock has moved up by 7.0%
  • Increasing Revenue

    Revenue is up for the last 2 quarters, 17.41M → 18.01M (in $), with an average increase of 3.4% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -36.54M → -43.96M (in $), with an average decrease of 20.3% per quarter
  • ADCT vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.5% return, outperforming this stock by 132.7%
  • ADCT vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 51.6% return, outperforming this stock by 139.6%
  • Price to Sales

    ForADCT every $1 of sales, investors are willing to pay $2.2, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

ADCT Adc Therapeutics Sa Financials in INR & Dollars

FY21Y/Y Change
Revenue
$33.9M
↑ 0.0%
Net Income
$-230.0M
↑ 0.0%
Net Profit Margin
-678.2%
↑ 0.0%
FY21Y/Y Change
Revenue
$33.9M
↑ 0.0%
Net Income
$-230.0M
↑ 0.0%
Net Profit Margin
-678.2%
↑ 0.0%
FY22Y/Y Change
Revenue
$209.9M
↑ 0.0%
Net Income
$-155.8M
↑ 0.0%
Net Profit Margin
-74.22%
↑ 0.0%
FY22Y/Y Change
Revenue
$209.9M
↑ 0.0%
Net Income
$-155.8M
↑ 0.0%
Net Profit Margin
-74.22%
↑ 0.0%
FY23Y/Y Change
Revenue
$69.6M
↑ 0.0%
Net Income
$-240.1M
↑ 0.0%
Net Profit Margin
-345.11%
↑ 0.0%
FY23Y/Y Change
Revenue
$69.6M
↑ 0.0%
Net Income
$-240.1M
↑ 0.0%
Net Profit Margin
-345.11%
↑ 0.0%
Q2 FY23Q/Q Change
Revenue
$19.3M
↑ 1.53%
Net Income
$-47.1M
↓ 20.71%
Net Profit Margin
-244.34%
↑ 68.56%
Q3 FY23Q/Q Change
Revenue
$14.5M
↓ 24.84%
Net Income
$-47.8M
↑ 1.46%
Net Profit Margin
-329.86%
↓ 85.52%
Q4 FY23Q/Q Change
Revenue
$16.8M
↑ 15.85%
Net Income
$-85.0M
↑ 77.86%
Net Profit Margin
-506.44%
↓ 176.58%
Q1 FY24Q/Q Change
Revenue
$18.1M
↑ 7.52%
Net Income
$-46.6M
↓ 45.19%
Net Profit Margin
-258.16%
↑ 248.28%
Q2 FY24Q/Q Change
Revenue
$17.4M
↓ 3.56%
Net Income
$-36.5M
↓ 21.59%
Net Profit Margin
-209.9%
↑ 48.26%
Q3 FY24Q/Q Change
Revenue
$18.0M
↑ 3.48%
Net Income
$-44.0M
↑ 20.32%
Net Profit Margin
-244.06%
↓ 34.16%
FY21Y/Y Change
Profit
$32.5M
-
FY22Y/Y Change
Profit
$205.3M
-
FY23Y/Y Change
Profit
$67.0M
-
Q2 FY23Q/Q Change
Profit
$18.0M
↓ 2.38%
Q3 FY23Q/Q Change
Profit
$14.1M
↓ 21.36%
Q4 FY23Q/Q Change
Profit
$15.6M
↑ 10.25%
Q1 FY24Q/Q Change
Profit
$14.7M
↓ 5.62%
Q2 FY24Q/Q Change
Profit
$15.4M
↑ 4.46%
Q3 FY24Q/Q Change
Profit
$17.2M
↑ 11.79%
FY21Y/Y Change
Operating Cash Flow
$-233.4M
↑ 0.0%
Investing Cash Flow
$-6.7M
↑ 0.0%
Financing Cash Flow
$267.4M
↑ 0.0%
FY21Y/Y Change
Operating Cash Flow
$-233.4M
↑ 0.0%
Investing Cash Flow
$-6.7M
↑ 0.0%
Financing Cash Flow
$267.4M
↑ 0.0%
FY22Y/Y Change
Operating Cash Flow
$-136.8M
↑ 0.0%
Investing Cash Flow
$-2.5M
↑ 0.0%
Financing Cash Flow
$-593.0K
↑ 0.0%
FY22Y/Y Change
Operating Cash Flow
$-136.8M
↑ 0.0%
Investing Cash Flow
$-2.5M
↑ 0.0%
Financing Cash Flow
$-593.0K
↑ 0.0%
Q2 FY23Q/Q Change
Operating Cash Flow
$-36.8M
↑ 149.31%
Investing Cash Flow
$-661.0K
↑ 0.0%
Financing Cash Flow
$74.7M
↓ 38232.14%
Q3 FY23Q/Q Change
Operating Cash Flow
$-34.0M
↓ 7.63%
Investing Cash Flow
$-661.0K
↑ 0.0%
Financing Cash Flow
$-2.3M
↓ 103.09%

Adc Therapeutics Sa Technicals Summary

Sell

Neutral

Buy

Adc Therapeutics Sa is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Adc Therapeutics Sa (ADCT) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Adc Therapeutics Sa logo
2.42%
-40.28%
-66.2%
-87.93%
-94.3%
Regeneron Pharmaceuticals, Inc. logo
-1.42%
-40.28%
-29.31%
11.08%
44.83%
Beone Medicines Ltd logo
17.63%
36.87%
64.37%
45.89%
71.3%
Vertex Pharmaceuticals Incorporated logo
1.94%
4.92%
19.37%
108.73%
123.83%
Alnylam Pharmaceuticals, Inc. logo
-8.03%
-0.89%
66.53%
52.9%
126.66%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Adc Therapeutics Sa logo
NA
NA
NA
0.0
-7.06
-0.21
NA
-1.78
Regeneron Pharmaceuticals, Inc. logo
17.86
17.86
1.01
43.09
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
NA
NA
NA
1.43
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.34
18.07
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.57
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Adc Therapeutics Sa logo
Buy
$173.1M
-94.3%
NA
-300.0%
Regeneron Pharmaceuticals, Inc. logo
Buy
$73.8B
44.83%
17.86
31.07%
Beone Medicines Ltd logo
NA
$29.1B
71.3%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Buy
$124.9B
123.83%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$31.4B
126.66%
NA
-12.37%

About Adc Therapeutics Sa

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Organization
Adc Therapeutics Sa
Employees
273
CEO
Dr. Ameet Mallik M.B.A., M.S.
Industry
Health Technology

Management People of Adc Therapeutics Sa

NameTitle
Dr. Ameet Mallik M.B.A., M.S.
CEO & Director
Mr. Jose I. Carmona M.B.A.
Chief Financial Officer
Dr. Mohamed Zaki M.D., Ph.D.
Chief Medical Officer
Ms. Lisa Michelle Kallebo
Corporate Controller & Chief Accounting Officer
Dr. David S. Ege Ph.D.
Chief Technical Officer
Dr. Patrick van Berkel Ph.D.
Chief Scientific Officer
Ms. Marcy Graham
Investor Relations Officer
Mr. Peter J. Graham Esq.
Secretary & Chief Legal Officer
Ms. Eugenia Litz
Vice President of Investor Relations & Corporate Communications
Ms. Kimberly Pope
Senior VP & Chief People Officer

Important FAQs about investing in ADCT Stock from India :

What is Adc Therapeutics Sa share price today?

Adc Therapeutics Sa share price today stands at $1.69, Open: $1.79 ; Previous Close: $1.79 ; High: $1.77 ; Low: $1.67 ; 52 Week High: $5.38 ; 52 Week Low: $1.39.

The stock opens at $1.79, after a previous close of $1.79. The stock reached a daily high of $1.77 and a low of $1.67, with a 52-week high of $5.38 and a 52-week low of $1.39.

Can Indians buy Adc Therapeutics Sa shares?

Yes, Indians can invest in the Adc Therapeutics Sa (ADCT) from India.

With INDmoney, you can buy Adc Therapeutics Sa at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Adc Therapeutics Sa at zero transaction cost.

How can I buy Adc Therapeutics Sa shares from India?

It is very easy to buy Adc Therapeutics Sa from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Adc Therapeutics Sa (ADCT) be purchased?

Yes, you can buy fractional shares of Adc Therapeutics Sa with INDmoney app.

What are the documents required to start investing in Adc Therapeutics Sa stocks?

To start investing in Adc Therapeutics Sa, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Adc Therapeutics Sa Stock (ADCT)?

Today’s highest price of Adc Therapeutics Sa (ADCT) is $1.77.

Today’s lowest price of Adc Therapeutics Sa (ADCT) is $1.67.

What is today's market capitalisation of Adc Therapeutics Sa?

Today's market capitalisation of Adc Therapeutics Sa ADCT is 173.1M

What is the 52 Week High and Low Range of Adc Therapeutics Sa Stock (ADCT)?

  • 52 Week High

    $5.38

  • 52 Week Low

    $1.39

What are the historical returns of Adc Therapeutics Sa (ADCT)?

  • 1 Month Returns

    2.42%

  • 3 Months Returns

    -40.28%

  • 1 Year Returns

    -66.2%

  • 5 Years Returns

    -94.3%

Who is the Chief Executive Officer (CEO) of Adc Therapeutics Sa ?

Dr. Ameet Mallik M.B.A., M.S. is the current Chief Executive Officer (CEO) of Adc Therapeutics Sa.